AASLD The Liver Meeting® 2023
MRI-Based Muscle Biomarkers linked to liver disease severity and progression
Why assess muscles in liver disease?
There is significant crosstalk between skeletal muscles and the liver, and a growing body of evidence places skeletal muscles at the center of the NAFLD pathogenic cascade 1. Importantly, sarcopenia is a common major complication in liver cirrhosis which negatively impacts outcomes in patients 2. Further, novel treatments for metabolic dysfunction have been shown in recent studies to be able to modulate muscle composition 3-5.
DID YOU KNOW?
AMRA’s latest research presents MAsS (Muscle Assessment Score) Biomarkers as a promising tool to identify physical frailty and sarcopenia and as a prognostic biomarker for liver disease.
Explore AMRA’s latest liver disease research presented at The Liver Meeting® leveraging AMRA’s MRI-based technology and biomarkers focusing along the spectrum of chronic liver disease.
Balkhed et al
●
●
#2077
NAFLD prevalence and predictors in patients with T2DM in primary care – Interim results from the EPSONIP study
Poster Hall A (plaza level)
1:00 – 2:00 PM , Nov 11
Balkhed et al
●
●
#2229
NAFLD, body and muscle composition profile in patients with T2D in primary care – Interim results from the EPSONIP study
Poster Hall A (plaza level)
1:00 – 2:00 PM , Nov 11
Forsgren et al
●
#214
Muscle fat infiltration is elevated in prefrail and moderately physically impaired patients – interim results from the prospective multi-center cirrhosis cohort study ACCESS-ESLD
Republic Ballroom (Sheraton)
4:45 PM , Nov 13
Forsgren et al
●
#3090
Muscle volume z-score is lower in high-risk patients awaiting LT – interim results from a liver transplant waitlist natural history study
Poster Hall A (plaza level)
1:00 – 2:00 PM , Nov 12
Linge et al
●
●
#2263
Two year of wasting with metabolic disorders – initial results on muscle composition from the longitudinal UK Biobank imaging study
Poster Hall C (second level)
1:00 – 2:00 PM , Nov 11
Siddiqui et al
●
#3002
Adipose Compartments Predict Severity of Portal Hypertension Among Patients with Cirrhosis
Poster Hall A (plaza level)
1:00 – 2:00 PM , Nov 12
Chavez et al
●
#2021
Characterizing Skeletal Muscle Composition and Function in Patients with Chronic Liver Disease
Poster Hall A (plaza level)
1:00 – 2:00 PM , Nov 11
Jamil et al
●
#2088
Patients with NASH Cirrhosis have similar muscle compositions as non-NASH patients as Assessed by Novel MRI-Based Muscle Assessment Technology
Poster Hall A (plaza level)
1:00 – 2:00 PM , Nov 11
Forsgren et al
●
#3089
Muscle fat infiltration, a potential risk marker, increases rapidly in patients with compensated liver cirrhosis – interim results from the prospective multi-center cirrhosis cohort study ACCESS-ESLD
Poster Hall A (plaza level)
1:00 – 2:00 PM , Nov 12
Advance clinical research with AMRA® Researcher including the novel MAsS (Muscle Assessment Score) biomarkers
AMRA’s MRI-based body composition analysis service, AMRA® Researcher, with its unique and patented technology and informatics platform, provides accurate and precise abdominal fat and muscle measurements. In addition to the volumetric measurements, AMRA provides muscle health biomarkers invariant to the confounding effects of sex and BMI, referred to as the Muscle Assessment Score (MAsS).6
Read more about our clinical service AMRA®MAsS Scan →
AMRA® MAsS Scan utilizes AMRA® Profiler 4, which is a US FDA 510(k) cleared medical device and has an MDEL (Medical Device Establishment Licence) in Canada, where it is indicated for use as a magnetic resonance diagnostic device software application for non-invasive fat and muscle evaluation intended to be interpreted by a trained clinician to yield information that may assist in diagnosis.
Why MAsS?
The MAsS biomarkers, muscle volume z-score and muscle fat infiltration, can be used to detect muscle composition phenotypes such as the adverse muscle composition phenotype (high muscle fat and low volume).7
The adverse muscle composition phenotype has been shown to independently predict all-cause mortality in the general population and nonalcoholic fatty liver disease (NAFLD). Furthermore, muscle volume z-score and muscle fat infiltration have been linked to incident comorbidities, hospitalization, and poor functional performance in the general population and in NAFLD. 6-9
The link between muscle composition and chronic liver disease and outcomes, is well established in literature and the impact on muscle health by novel treatments of metabolic dysfunction is emerging. Therefore, these MAsS biomarkers may be crucial for clinical research investigating aspects of liver disease and potential targets for treatment thereof.
Resources
Follow us on social media
Follow AMRA Medical on social media for the latest updates in body composition and precision medicine. Please use your preferred social media platform below:
Latest News
-
Muscles, Metabolic Surgery, and MASLD: AMRA Medical to Highlight Latest Research Exploring the Connection Between at EASL 2026
References
1. Chakravarthy MV, Siddiqui MS, Forsgren MF, Sanyal AJ. Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne). 2020;11:592373.
2. Lai JC, Tandon P, Bernal W, Tapper EB, Ekong U, Dasarathy S, et al. Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(3):1611-44.
3. Patel KV, Pandey A, Ayers C, J. L, Dahlqvist Leinhard O, Joshi PH, et al. Effect of liraglutide on muscle fat infiltration in adults with overweight or obesity: a randomised clinical trial. Diabetologica. 2022;65(Suppl 1):S59.
4. Linge J, Neeland I, Dahlqvist Leinhard O, Sattar N, Fernandez Lando L, Bray R, et al. Tirzepatide achieves significant weight loss without adverse effects on muscle composition (SURPASS-3 MRI). Diabetologia. 2023;66(Suppl 1):S3.
5. Sattar N, Linge J, Neeland I, Dahlqvist Leinhard O, Fernandez Lando L, Bray R, et al. Tirzepatide reduces muscle fat infiltration relative to insulin degludec in people with type 2 diabetes (SURPASS-3 MRI). Diabetologia. 2023;66(Suppl 1):S3.
6. Linge J, Heymsfield SB, Dahlqvist Leinhard O. On the Definition of Sarcopenia in the Presence of Aging and Obesity-Initial Results from UK Biobank. J Gerontol A Biol Sci Med Sci. 2020;75(7):1309-16.
7. Linge J, Nasr P, Sanyal AJ, Dahlqvist Leinhard O, Ekstedt M. Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD. JHEP Rep. 2023;5(3):100663
8. Linge J, Petersson M, Forsgren MF, Sanyal AJ, Dahlqvist Leinhard O. Adverse muscle composition predicts all-cause mortality in the UK Biobank imaging study. J Cachexia Sarcopenia Muscle. 2021;12(6):1513-26.
9. Linge J, Ekstedt M, Dahlqvist Leinhard O. Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD. JHEP Rep. 2021;3(1):100197.